Under existing rules, many clinical trials are supposed to report their results to ClinicalTrials.gov, a public database run by the National Library of Medicine. The FDA can fine companies that fail to comply, though enforcement has historically been inconsistent.

Why unpublished data matters

When trial results go unreported, several problems follow:

• Incomplete medical knowledge. Doctors prescribing a medication may not know about trials that found the drug less effective or more risky than published studies suggest.
• Wasted research effort. Scientists may unknowingly repeat studies that have already been done, or design trials based on an incomplete picture of the evidence.
• Publication bias. Studies with positive results are more likely to be published than those with negative or unclear findings, which can skew the apparent effectiveness of a treatment.

What happens next

The FDA's call represents a step toward greater transparency in drug development, but it remains to be seen how quickly companies will respond and whether the agency will enforce penalties for continued non-compliance.

The push for missing trial data comes amid broader efforts to make medical research more open and accessible to the public and the scientific community.